Optical

Empowering the Future of Optometry: Axcel Learning Partners with KMK Optometry to Redefine Board Exam Preparation

Retrieved on: 
Thursday, March 28, 2024
Other Professional Services, Optical, General Health, Health, Other Education, Professional Services, Education, Training, Culture, Growth, KMK, Environment, Partnership, NBEO, School, Optometry, Student, Heart, Alpine, Multimedia, Management

Axcel Learning (Axcel), a professional education business backed by Alpine Investors (Alpine), today announced a new partnership with KMK Optometry (KMK), the premier provider of comprehensive optometry board exam test preparation and coaching services.

Key Points: 
  • Axcel Learning (Axcel), a professional education business backed by Alpine Investors (Alpine), today announced a new partnership with KMK Optometry (KMK), the premier provider of comprehensive optometry board exam test preparation and coaching services.
  • For 20 straight years, KMK has been the #1 choice for Optometry board review with the industry’s only fully comprehensive review courses.
  • “Our essence is defined by our commitment to continuous improvement, connection and academic integrity,” said Melissa Cheatham, Co-Founder of KMK.
  • DC Advisory served as the exclusive financial advisor to KMK Optometry.

Global Sports Optics Analysis 2023: A $2.73 Billion Market by 2029 Featuring Key vendors - Nikon, Swarovski, Beretta, Vortex, Leica Camera, Carlyle group, ATN, and Trijicon Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024
General Sports, Optical, Health, Sports, Astronomy, Culture, Camping, Telescope, Growth, Sport, Environment, COVID-19, ZEISS, Law enforcement, Sale, SFL, Asian Games, Olympic Games, Water, Golf, Snow, Telescopic sight

The "Global Sports Optics Market: Analysis By Type, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Sports Optics Market: Analysis By Type, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global sports optics market value stood at US$2.17 in 2023, and is expected to reach US$2.73 billion by 2029.
  • The market is expected to grow at a CAGR of 3.94% over the projected period of 2024-2029.
  • The report provides the bifurcation of the sports optics market into five segments on the basis of type: binoculars, rifle scopes, rangefinders, telescopes, and others.

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Genetics, Clinical Trials, Form, Telephone, Sale, Public expenditure, Security (finance), Prospectus, Broadridge Financial Solutions, Therapy, J.P. Morgan & Co.

The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke.

Key Points: 
  • The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke.
  • The offering is expected to close on or about April 2, 2024, subject to the satisfaction of customary closing conditions.
  • Stoke has also granted the underwriters a 30-day option to purchase up to an additional 1,388,893 shares of common stock in connection with the offering.
  • A preliminary prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC.

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, RASP, Environment, Patient, NDA, University, Quality of life, Clinical trial, Therapy, University of California, Telecanthus, FDA, Food, DSM-IV codes, Pharmaceutical industry

Following discussions with the FDA, Aldeyra intends to initiate a dry eye chamber clinical trial in the first half of 2024.

Key Points: 
  • Following discussions with the FDA, Aldeyra intends to initiate a dry eye chamber clinical trial in the first half of 2024.
  • In the proposed dry eye chamber trial, patients will be administered vehicle (the drug product without the active ingredient) before and during exposure to a dry eye chamber.
  • The design and statistical powering for the proposed trial are derived from four previously completed dry eye chamber clinical trials with reproxalap.
  • ET today, March 28, 2024, to discuss the clinical development plan for resubmission of the new drug application for reproxalap in dry eye disease.

Wiregrass Museum of Art to Loan EnChroma Glasses to Color Blind Visitors

Retrieved on: 
Wednesday, March 27, 2024
University, Primary, Secondary, Education, Optical, Destinations, Travel, Neurology, People with Disabilities, Family, Science, Arts, Museums, Vacation, Entertainment, Other Science, Consumer, Health, Museum, CVD, Library, WMA, Birmingham Museum, Nature, Student, Woman, Credit, Color vision, Retina, Wiregrass Museum of Art, Paratriathlon, Multimedia, Collection, EnChroma

Wiregrass Museum of Art (WMA) and EnChroma® – creators of glasses for color blindness – today announced that WMA will loan EnChroma glasses to visitors who are red-green color blind so they can more fully experience the colors in its exhibits.

Key Points: 
  • Wiregrass Museum of Art (WMA) and EnChroma® – creators of glasses for color blindness – today announced that WMA will loan EnChroma glasses to visitors who are red-green color blind so they can more fully experience the colors in its exhibits.
  • While people with normal color vision see over one million shades of color, the red-green color blind only see an estimated 10% of hues and shades.
  • EnChroma is the lead advocate for “color accessibility,” helping universities, state and national parks, libraries, museums, and other organizations purchase and loan EnChroma glasses to color blind students and guests.
  • They enhance color for approximately 80% of red-green color blind people who have all three of the color cones in their retina functioning properly.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Stoke Therapeutics Announces Proposed Public Offering

Retrieved on: 
Tuesday, March 26, 2024
Health, Genetics, General Health, Pharmaceutical, Optical, Biotechnology, Form, Telephone, Research, Sale, Public expenditure, Security (finance), Prospectus, Form S-3, Broadridge Financial Solutions, Therapy, J.P. Morgan & Co.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock.
  • In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
  • All of the shares of common stock are being offered by Stoke.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Optical, Health, Research and development, PIN, Growth, NBY, G&A, Co-promotion, Amazon (company), OTC, Marketing, NovaBay Pharmaceuticals, Pharmaceutical industry

(NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.

Key Points: 
  • (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
  • Net product revenue for the fourth quarter of 2023 included $2.8 million from the eyecare and wound care segment, and $0.9 million from the skincare segment.
  • Gross margin on net product revenue for the fourth quarter of 2023 was 49%, compared with 48% for the fourth quarter of 2022.
  • Research & development (R&D) expenses also decreased for the fourth quarter of 2023 to $4 thousand, versus $66 thousand for the prior-year period.

Center For Sight Implants New FDA-Approved iDose®TR Device

Retrieved on: 
Tuesday, March 26, 2024
Surgery, Medical Devices, FDA, Hospitals, Biotechnology, Other Health, Health, General Health, Optical, Optic nerve, Ocular hypertension, Paratriathlon, Patient, Cataract, Eye, Multimedia, Intraocular pressure, Food, Medical device

The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.

Key Points: 
  • The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.
  • The device consistently distributes a travoprost formula to help reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
  • is a member of the US Eye Physician Advisory Board and is a Cataract and Glaucoma Surgeon at Center For Sight.
  • Speaking of the device, he shares, “We found the device and medication formula to work very well in our study patients.

MyEyeDr. Partners with Prevent Blindness to Promote Eye Health and Safety During April 8 Solar Eclipse, Gives Away Solar Glasses at 400+ Locations

Retrieved on: 
Monday, March 25, 2024
General Health, Other Consumer, Consumer, Health, Optical, Partnership, Telecanthus, Patient, Multimedia, Glaucoma, Cataract, Heart, Safety

Gives Away Solar Glasses at 400+ Locations (Graphic: Business Wire)

Key Points: 
  • Gives Away Solar Glasses at 400+ Locations (Graphic: Business Wire)
    Through this effort, and in partnership with Prevent Blindness , MyEyeDr.
  • is giving away expert-approved solar eclipse glasses in 438 offices across 20 states in the eclipse’s path of totality.
  • to get a pair of free solar eclipse glasses, at participating locations while supplies last.
  • For more information on MyEyeDr., important details about eye health, or to find a nearby location, please visit www.myeyedr.com .